• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI Executive AssistantNEW
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI Executive AssistantNEW
  • Settings
  • RSS Feeds
PublishGo to AppAI Helper
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI employees for your businessNEW
    Legal
    Terms of usePrivacy policyCookie policy

    Procaps Issues Shareholder Letter Update

    9/18/24 8:10:00 AM ET
    $PROC
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $PROC alert in real time by email

    MIAMI and BARRANQUILLA, Colombia, Sept. 18, 2024 (GLOBE NEWSWIRE) -- Procaps Group, S.A. (NASDAQ:PROC) ("Procaps" or the "Company"), a leading integrated LatAm healthcare and pharmaceutical services, today issued the below letter to shareholders from José Antonio Vieira, CEO of Procaps, with updates on the Company's restructuring and strategic plan projects.

    "Dear Shareholders,

    We are pleased to update you on several significant developments as we continue to move forward with our strategic plan and financial restructuring efforts.

    Forbearance Agreements

    We have successfully signed consolidated forbearance agreements covering approximately an aggregate of $209 million in debt. These agreements are a crucial step in providing the Company with the flexibility needed to continue supporting our core business operations while we work toward a comprehensive debt restructuring solution. The forbearance agreements temporarily pause payments and prevent lenders from enforcing remedies, giving us the ability to focus on our long-term strategy.

    Shareholder Investment

    We have received a $5 million investment from the Company's controlling shareholders via a subordinated promissory note, which will provide temporary support for our immediate working capital needs. However, we recognize that this is a short-term measure, and the Company's cash flow remains under significant pressure. This underscores the urgency of executing our restructuring plan, securing additional financing, and optimizing our operations to address the Company's liquidity needs.

    We continue making progress on other fronts:

    Internal Investigation and Financial Reporting: We continue to work diligently alongside our legal and accounting advisors, in cooperation with our external auditors, to complete the internal investigation and report our financial statements. Our focus remains on ensuring the accuracy and completeness of our financial reporting.

    Debt Restructuring: Simultaneously, we are working closely with our financial advisors to develop a comprehensive, long-term restructuring plan. FTI Consulting, Inc. has been engaged to conduct an independent business plan analysis, which is already well underway. This independent review will provide us with critical insights to support our efforts in restructuring our debt and positioning Procaps for sustainable financial health moving forward.

    Looking Forward

    While we continue to face challenges, we remain focused on executing our strategic plan. Our goals include improving operational efficiency, optimizing cash flow, and securing the financial flexibility required to support our long-term growth objectives.

    Thank you for your continued support and patience as we complete the internal investigation, while working diligently to strengthen our financial position and create sustainable value for all our stakeholders. We will continue to provide updates as we reach key milestones in our journey.

    Sincerely,

    José Antonio Vieira

    CEO of Procaps Group"

    This press release shall not constitute an offer to sell or the solicitation of an offer to buy any securities, nor shall there be any sale of any securities in any state or jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction.

    About Procaps Group

    Procaps Group, S.A. ("Procaps") (NASDAQ:PROC) is a leading developer of pharmaceutical and nutraceutical solutions, medicines, and hospital supplies that reach more than 50 countries in all five continents. Procaps has a direct presence in 13 countries in the Americas and nearly 5,000 employees working under a sustainable model. Procaps develops, manufactures, and markets over-the-counter (OTC) pharmaceutical products, prescription pharmaceutical drugs (Rx), nutritional supplements, and high-potency clinical solutions.

    For more information, visit www.procapsgroup.com or Procaps' investor relations website investor.procapsgroup.com.

    Investor Contact:

    Melissa Angelini

    [email protected]

    +1 754 260-6476

    investor.procapsgroup.com

    Forward-Looking Statements

                    

    This press release includes "forward-looking statements" within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934. Forward-looking statements may be identified by the use of words such as "forecast," "intend," "seek," "target," "anticipate," "believe," "expect," "estimate," "plan," "outlook," "goal," "objective," "will," "may," "should," "can," "project" and other similar expressions that predict or indicate future events, objectives, results or trends or that are not statements of historical matters. Such forward-looking statements include, without limitation, projected financial information, the Company's expectations about the timing of completion of the internal investigation and filing of the 2023 20-F, the Company's statements regarding seeking additional financing, statements related to the Company's plans, outlook and strategy, other Company initiatives and objectives or forecasts related to the Company's business, performance and industry. These forward-looking statements involve substantial risks and uncertainties, or assumptions that may cause actual results or performance to be materially different from those expressed or implied by these forward-looking statements, and actual results could vary materially from these forward-looking statements. Factors that may cause future results to differ materially from management's current expectations include, among other things, the discovery of additional information relevant to the internal investigation; the conclusions of management (and the timing of the conclusions) concerning matters relating to the internal investigation; the timing of the review by, and the conclusions of, the Company's independent registered public accounting firm regarding the internal investigation and the Company's financial statements; the possibility that errors may be identified; the risk that the completion and filing of the Form 20-F will take longer than expected; the inability to successfully implement or execute on the Company's strategic objectives or initiatives; the inability to obtain additional financing; the inability to successfully implement or execute on our restructuring plans; changes in applicable laws or regulations; the possibility that the Company may be adversely affected by other economic, business, and/or competitive factors; the inability of the Company to execute on its expense reductions plans or growth initiatives; and other risks and uncertainties indicated from time to time in documents filed or to be filed with the Securities and Exchange Commission ("SEC") by the Company. The Company disclaims any obligation to update information contained in these forward-looking statements whether as a result of new information, future events, or otherwise.



    Primary Logo

    Get the next $PROC alert in real time by email

    Crush Q3 2025 with the Best AI Executive Assistant

    Stay ahead of the competition with Tailforce.ai - your AI-powered business intelligence partner.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Tailforce.ai

    Recent Analyst Ratings for
    $PROC

    DatePrice TargetRatingAnalyst
    More analyst ratings

    $PROC
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • Procaps Group Receives Delisting Notice From Nasdaq

      MIAMI and BARRANQUILLA, Columbia, Feb. 03, 2025 (GLOBE NEWSWIRE) -- Procaps Group, S.A. (NASDAQ:PROC) ("Procaps" or the "Company"), a leading integrated LatAm healthcare and pharmaceutical services company, today announced that the Company received a notice from The Nasdaq Stock Market LLC ("Nasdaq") that it has determined to delist the Company's ordinary shares on Nasdaq. The delisting is a result of the Company's failure to demonstrate compliance with Nasdaq Listing Rules 5250(c)(1) and 5250(c)(2) for failing to file periodic and interim financial reports. As a result of the forgoing, the Company's ordinary shares are expected to commence trading on the Expert Market operated by the OTC

      2/3/25 8:50:00 AM ET
      $PROC
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Procaps Group Receives Additional Delinquency Letter

      MIAMI and BARRANQUILLA, Columbia, Jan. 03, 2025 (GLOBE NEWSWIRE) -- Procaps Group, S.A. (NASDAQ:PROC) ("Procaps" or the "Company"), a leading integrated LatAm healthcare and pharmaceutical services company, today announced that, as anticipated, on December 31, 2024, the Company received notice from The Nasdaq Stock Market LLC ("Nasdaq") of an additional filing delinquency relating to the Company's interim financial statements for the period ended June 30, 2024. The interim financial statements were required to be filed with Nasdaq by December 31, 2024, but were not for the reasons previously disclosed in connection with the delay in the filing of the Company's Form 20-F for the fiscal yea

      1/3/25 4:15:00 PM ET
      $PROC
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Procaps Group Announces Key Shareholder and Board Decisions, Committee Restructuring, and Leadership Updates

      MIAMI and BARRANQUILLA, Colombia, Dec. 20, 2024 (GLOBE NEWSWIRE) -- Procaps Group, S.A. (NASDAQ:PROC) ("Procaps" or the "Company"), a leading integrated LatAm healthcare and pharmaceutical services company, today announced significant outcomes from its recent Shareholders Meeting and subsequent Board of Directors meeting. These include changes to the Board composition, restructuring of Board committees, and updates to its executive leadership team. The Shareholders Meeting marked an important milestone with the election of new members to the Board of Directors. The newly elected members bring a diverse range of expertise and strategic insight to guide Procaps' future growth. Newly app

      12/20/24 4:53:03 PM ET
      $PROC
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $PROC
    Financials

    Live finance-specific insights

    See more
    • Procaps Group Reports Third Quarter 2023 Results

      Net Revenues Increased 5% in 9M23 Year-over-Year on a Constant Currency Basis, Driven by 13% RX Growth Procaps Group, S.A. (NASDAQ:PROC) ("Procaps" or the "Company"), a leading integrated international healthcare and pharmaceutical services company, today announced its financial results for the three months ended September 30, 2023 ("3Q23") and the nine months ended September 30, 2023 ("9M23"). Financial Highlights 3Q23 & 9M23 Net revenues totaled $118 million for 3Q23, positively impacted by the performance of RX and OTC portfolios, offset by lower CDMO revenues. On a constant currency basis, net revenues increased by 2% in 3Q23. For 9M23, net revenues totaled $313 million, an incre

      12/26/23 5:40:00 PM ET
      $PROC
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Procaps Group Update on Third Quarter Results

      Procaps Group (NASDAQ:PROC) ("Procaps"), a leading integrated LatAm healthcare and pharmaceutical services company, today announced that it is postponing the previously-announced earnings conference call (currently scheduled for November 16, 2023) to a later date after Procaps publishes its results for the third quarter and nine months ended September 30, 2023 ("3Q23"). Procaps will host a conference call in conjunction with its release of the 3Q23 Results, and call/webcast details will be provided in advance of the call. About Procaps Group Procaps Group, S.A. ("Procaps") (NASDAQ:PROC) is a leading developer of pharmaceutical and nutraceutical solutions, medicines, and hospital supplie

      11/14/23 5:25:00 PM ET
      $PROC
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Procaps Group to Report Third Quarter and Nine Months 2023 Results on Tuesday November 14, 2023

      Company to Host Conference Call on Thursday November 16, 2023 at 10:30 a.m. Eastern Time Procaps Group (NASDAQ:PROC) ("Procaps"), a leading integrated LatAm healthcare and pharmaceutical services company, announced it will report its results for the third quarter and nine months ended September 30, 2023, after market closes on Tuesday, November 14, 2023. The Company will host a conference call and webcast on Thursday, November 16, 2023, at 10:30 a.m. Eastern time, to discuss the third quarter and nine months 2023 results. To access the call, please use the following information: Date: Thursday, November 16, 2023 Time: 10:30 a.m. ET Webcast: Cli

      11/10/23 11:37:00 AM ET
      $PROC
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $PROC
    Leadership Updates

    Live Leadership Updates

    See more
    • Procaps Group Announces Key Shareholder and Board Decisions, Committee Restructuring, and Leadership Updates

      MIAMI and BARRANQUILLA, Colombia, Dec. 20, 2024 (GLOBE NEWSWIRE) -- Procaps Group, S.A. (NASDAQ:PROC) ("Procaps" or the "Company"), a leading integrated LatAm healthcare and pharmaceutical services company, today announced significant outcomes from its recent Shareholders Meeting and subsequent Board of Directors meeting. These include changes to the Board composition, restructuring of Board committees, and updates to its executive leadership team. The Shareholders Meeting marked an important milestone with the election of new members to the Board of Directors. The newly elected members bring a diverse range of expertise and strategic insight to guide Procaps' future growth. Newly app

      12/20/24 4:53:03 PM ET
      $PROC
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Statement from the Board of Directors of Procaps Group

      Procaps Group (NASDAQ:PROC) ("Procaps"). Having completed the last ordinary meeting of 2023 on December 19th in which Ruben Minski acted as CEO of the Procaps Group for the last time, and taking into account that as of January 15th, 2024 he will take over as Executive Chairman of the Board, which resulted from a planned and communicated process to the market since February of this year, we would like to express our appreciation to Ruben for his inspiring and visionary leadership that has allowed Procaps to be a leading organization in the pharmaceutical sector in the Region today, recognized and valued in the market by the different stakeholders. Throughout his career in the Organization,

      12/21/23 6:45:00 PM ET
      $PROC
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Procaps Group Announces Appointment of Jose Antonio Vieira as Chief Executive Officer Starting 2024

      Procaps Group (NASDAQ:PROC) ("Procaps"), a leading integrated LatAm healthcare and pharmaceutical conglomerate, announced today a strategic leadership transition as Ruben Minski, founder and CEO of Procaps prepares to transition from the role of Chief Executive Officer to focus exclusively on his role as Executive Chairman of the Board, and the appointment of Jose Antonio Vieira as the new Chief Executive Officer of Procaps Group. The transition will be effective January 15, 2024. After over 45 years of visionary leadership and dedicated service, Ruben Minski has played a pivotal role in Procaps' growth and success, transforming it into a global leader in pharmaceutical innovation. Under

      11/22/23 8:30:00 AM ET
      $PROC
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $PROC
    SEC Filings

    See more
    • SEC Form 6-K filed by Procaps Group S.A.

      6-K - Procaps Group, S.A. (0001863362) (Filer)

      2/19/25 8:56:19 AM ET
      $PROC
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 6-K filed by Procaps Group S.A.

      6-K - Procaps Group, S.A. (0001863362) (Filer)

      2/3/25 9:00:03 AM ET
      $PROC
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 6-K filed by Procaps Group S.A.

      6-K - Procaps Group, S.A. (0001863362) (Filer)

      1/16/25 8:30:04 AM ET
      $PROC
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $PROC
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • SEC Form 3: New insider Manieu Alexandre Weinstein claimed ownership of 15,877,516 units of Ordinary Shares

      3 - Procaps Group, S.A. (0001863362) (Issuer)

      10/12/21 9:32:55 AM ET
      $PROC
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 3: New insider Minski Ruben claimed ownership of 31,338,454 units of Ordinary Shares

      3 - Procaps Group, S.A. (0001863362) (Issuer)

      10/8/21 5:22:21 PM ET
      $PROC
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 3: New insider Minski Jose claimed ownership of 17,960,146 units of Ordinary Shares

      3 - Procaps Group, S.A. (0001863362) (Issuer)

      10/8/21 5:20:55 PM ET
      $PROC
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $PROC
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • Amendment: SEC Form SC 13D/A filed by Procaps Group S.A.

      SC 13D/A - Procaps Group, S.A. (0001863362) (Subject)

      12/3/24 7:20:10 PM ET
      $PROC
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Amendment: SEC Form SC 13D/A filed by Procaps Group S.A.

      SC 13D/A - Procaps Group, S.A. (0001863362) (Subject)

      10/29/24 9:46:26 PM ET
      $PROC
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Amendment: SEC Form SC 13D/A filed by Procaps Group S.A.

      SC 13D/A - Procaps Group, S.A. (0001863362) (Subject)

      10/28/24 8:42:14 PM ET
      $PROC
      Biotechnology: Pharmaceutical Preparations
      Health Care